The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset
Abstract
INTRODUCTION: The recent failure of several clinical trials on anti-β-amyloid (Aβ) drugs in Alzheimer's disease (AD) suggested earlier intervention in the disease course. Secondary prevention trials have been started in autosomal-dominant AD (ADAD) individuals without cognitive dysfunction and in cognitively healthy subjects at risk of developing sporadic AD (SAD). AREAS COVERED: Herein, the authors discuss prevention trials in ADAD and SAD, with a focus on the anti-Aβ monoclonal antibodies solanezumab and gantenerumab presently in Phase III clinical development. These therapies are also being tested in the Dominantly Inherited Alzheimer's Network Trials Unit (DIAN-TU). EXPERT OPINION: Anti-Aβ monoclonal antibodies are being tested in subjects at the preclinical stage of ADAD and even in symptom-free subjects at risk of developing SAD. The subsequent DIAN-TU Adaptive Prevention Trial is a 4-year study that will assess whether such biomarker effects may stop the progress of the AD process, preventing cognitive symptoms. The hope is to interfere in the disease course when it is not too late. A clinical success of these prevention trials would represent the proof of the Aβ hypothesis of AD.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Preliminary results from the BAN2401 studies revealed a treatment-afflicted effect of a reduction in cerebral amyloid load in Alzheimer's disease patients, together with a slowing of cognitive deterioration.
“The preliminary results from the BAN2401 studies revealed a treatment-afflicted effect of a reduction in cerebral amyloid load in AD patients, together with a slowing of cognitive deterioration (Panza et al., 2018).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Panza et al., 2018
First results from aducanumab and BAN2401 trials suggested a treatment-related reduction in cerebral amyloid burden in agreement with deceleration of cognitive decline in patients with prodromal and very mild AD.
“First results from aducanumab and BAN2401 trials suggested, at first, a treatment-related result of reducing in cerebral amyloid burden in agreement to deceleration of cognitive decline in patients with prodromal and very mild AD.71,72”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [72]
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · see citing works
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · see citing works
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069 · see citing works
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411 · see citing works
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396 · see citing works
Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689 · see citing works
Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042 · see citing works
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · see citing works
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · see citing works
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · see citing works
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · see citing works
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · see citing works
Neuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336 · see citing works
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224 · see citing works
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B., Younkin, S. G., et al. (2001) · Nature Neuroscience · doi:10.1038/nn0901-887 · Cited by 1,209 · see citing works
Cognitive frailty: Rational and definition from an (I.A.N.A./I.A.G.G.) International Consensus Group
Kelaiditi, E., Cesari, M., Canevelli, M., van Kan, G. A., Ousset, P., Guyonnet, S., Ritz, P., Duveau, F., Soto, M., Provencher, V., et al. (2013) · The journal of nutrition health & aging · doi:10.1007/s12603-013-0367-2 · Cited by 1,114 · see citing works
The Preclinical Alzheimer Cognitive Composite: Measuring Amyloid-Related Decline
Donohue, M. C., Sperling, R. A., Salmon, D. P., Rentz, D. M., Raman, R., Thomas, R. G., Weiner, M., & Aisen, P. S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.803 · Cited by 860 · see citing works
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764 · see citing works
The A4 Study: Stopping AD Before Symptoms Begin?
Sperling, R. A., Rentz, D. M., Johnson, K. A., Karlawish, J. H., Donohue, M., Salmon, D. P., & Aisen, P. S. S. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007941 · Cited by 756 · see citing works
Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
Bertram, L., & Tanzi, R. E. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2494 · Cited by 747 · see citing works
Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70167-4 · Cited by 725 · see citing works
Three dimensions of the amyloid hypothesis: time, space and 'wingmen'
Musiek, E. S., & Holtzman, D. M. (2015) · Nature Neuroscience · doi:10.1038/nn.4018 · Cited by 697 · see citing works
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651 · see citing works
Jack, C. R., Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22628 · Cited by 602 · see citing works
Bateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., Salloway, S., Sperling, R. A., Windisch, M., & Xiong, C. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt59 · Cited by 573 · see citing works
Reiman, E. M., Quiroz, Y. T., Fleisher, A. S., Chen, K., Velez-Pardo, C., Jimenez-Del-Rio, M., Fagan, A. M., Shah, A. R., Alvarez, S., Arbelaez, A., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70228-4 · Cited by 541 · see citing works
Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522 · see citing works
Lemere, C. A., Lopera, F., Kosik, K. S., Lendon, C. L., Ossa, J., Saido, T. C., Yamaguchi, H., Ruiz, A., Martinez, A., Madrigal, L., et al. (1996) · Nature Medicine · doi:10.1038/nm1096-1146 · Cited by 487 · see citing works
Tan, C.-C., Yu, J.-T., Wang, H.-F., Tan, M.-S., Meng, X.-F., Wang, C., Jiang, T., Zhu, X.-C., & Tan, L. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132690 · Cited by 484 · see citing works
Donohue, M. C., Sperling, R. A., Petersen, R., Sun, C.-K., Weiner, M. W., Aisen, P. S., & Initiative, F. T. A. D. N. (2017) · JAMA · doi:10.1001/jama.2017.6669 · Cited by 452 · see citing works
Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448 · see citing works
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431 · see citing works
Cognitive frailty, a novel target for the prevention of elderly dependency
Ruan, Q., Yu, Z., Ma, C., Bao, Z., Li, J., & He, W. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.12.004 · Cited by 381 · see citing works
Coric, V., van Dyck, C. H., Salloway, S., Andreasen, N., Brody, M., RICHTER, R. W., Soininen, H. S., Thein, S., Shiovitz, T. M., Pilcher, G. D., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.2194 · Cited by 374 · see citing works
Lopera, F. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340027028 · Cited by 351 · see citing works
Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments
Reiman, E. M., Langbaum, J. B. S., Fleisher, A., Caselli, R. J., Chen, K., Ayutyanont, N., Quiroz, Y. T., Kosik, K. S., Lopera, F. J., & Tariot, P. N. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-0059 · Cited by 340 · see citing works
Vassar, R. J., Kuhn, P., Haass, C., Kennedy, M. E., Rajendran, L., Wong, P. C., & Lichtenthaler, S. F. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12715 · Cited by 329 · see citing works
Adolfsson, O., Pihlgren, M., Toni, N., Varisco, Y., Buccarello, A. L., Antoniello, K., Lohmann, S., Piorkowska, K., Gafner, V., Atwal, J. K., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.4742-11.2012 · Cited by 317 · see citing works
Advances in the prevention of Alzheimer's disease and dementia
Solomon, A., Mangialasche, F., Richard, E., Andrieu, S., Bennett, D., Breteler, M. M. B., Fratiglioni, L., Hooshmand, B., Khachaturian, A. S., Schneider, L. S. S., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12178 · Cited by 316 · see citing works
Bateman, R. J., Benzinger, T. L., Berry, S., Clifford, D. B., Duggan, C., Fagan, A. M., Fanning, K., Farlow, M. R., Hassenstab, J., McDade, E. M., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.07.005 · Cited by 303 · see citing works
Andrieu, S., Coley, N., Lovestone, S., Aisen, P. S., & Vellas, B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00153-2 · Cited by 293 · see citing works
Safety and biomarker effects of solanezumab in patients with Alzheimer's disease
Farlow, M. R., Arnold, S. E., van Dyck, C. H., Aisen, P. S. S., Snider, B. J., Porsteinsson, A. P., Friedrich, S. W., Dean, R. A., Gonzales, C., Sethuraman, G., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.09.224 · Cited by 280 · see citing works
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182309fa5 · Cited by 258 · see citing works
Lopera, F. J. (1997) · JAMA · doi:10.1001/jama.277.10.793 · Cited by 255 · see citing works
Fleisher, A., Chen, K., Quiroz, Y. T., Jakimovich, L. J., Gomez, M. G., Langois, C. M., Langbaum, J. B. S., Ayutyanont, N., Roontiva, A., Thiyyagura, P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70227-2 · Cited by 242 · see citing works
Morris, J. C., Aisen, P. S. S., Bateman, R. J., Benzinger, T. L. S., Cairns, N. J., Fagan, A. M., Ghetti, B. F., Goate, A., Holtzman, D. M., Klunk, W. E., et al. (2012) · Clinical Investigation · doi:10.4155/cli.12.93 · Cited by 205 · see citing works
Immunotherapy for Alzheimer’s disease: hoops and hurdles
Lemere, C. A. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-36 · Cited by 196 · see citing works
Siemers, E., Friedrich, S. W., Dean, R. A., Gonzales, C., Farlow, M. R., Paul, S. M., & Demattos, R. B. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cb577a · Cited by 192 · see citing works
Alzheimer disease pathology as a host response
Castellani, R. J., Lee, H.-G., Zhu, X., Perry, G., & Smith, M. A. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318177eaf4 · Cited by 171 · see citing works
The cell biology of Alzheimer's disease: uncovering the secrets of secretases
Walter, J., Kaether, C., Steiner, H., & Haass, C. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00253-1 · Cited by 160 · see citing works
Reiman, E. M., Langbaum, J. B. S., & Tariot, P. N. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.91 · Cited by 156 · see citing works
Lannfelt, L., Möller, C., Basun, H., Osswald, G., Sehlin, D., Satlin, A., Logovinsky, V., & Gellerfors, P. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt246 · Cited by 152 · see citing works
Sehlin, D., Englund, H., Simu, B., Karlsson, M., Ingelsson, M., Nikolajeff, F. K., Lannfelt, L., & Pettersson, F. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032014 · Cited by 150 · see citing works
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials
Moulder, K. L., Snider, B., Mills, S. L., Buckles, V. D., Santacruz, A. M., Bateman, R. J., & Morris, J. C. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt213 · Cited by 142 · see citing works
Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial
Mills, S., Mallmann, J., Santacruz, A. M., Fuqua, A., Carril, M. M. G., Aisen, P. S., Althage, M. C., Belyew, S., Benzinger, T. L. S., Brooks, W. S., et al. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.07.017 · Cited by 139 · see citing works
Du, Y. (2003) · Brain · doi:10.1093/brain/awg191 · Cited by 136 · see citing works
Ma, Q., Lim, G. P., Harris‐White, M. E., Yang, F., Ambegaokar, S. S., Ubeda, O. J., Glabe, C. G., Teter, B., Frautschy, S. A., & Cole, G. M. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20734 · Cited by 126 · see citing works
Tayeb, H. O., Murray, E. D., Price, B. H., & Tarazi, F. I. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.789856 · Cited by 119 · see citing works
Targeting Cognitive Frailty: Clinical and Neurobiological Roadmap for a Single Complex Phenotype
Panza, F., Seripa, D., Solfrizzi, V., Tortelli, R., Greco, A., Pilotto, A., & Logroscino, G. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150358 · Cited by 119 · see citing works
Self-citationYamada, K., Yabuki, C., Seubert, P., Schenk, D., Hori, Y., Ohtsuki, S., Terasaki, T., Hashimoto, T., & Iwatsubo, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2021-09.2009 · Cited by 117 · see citing works
Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change
Soldan, A., Pettigrew, C. A., Cai, Q., Wang, M., Moghekar, A., O’Brien, R., Selnes, O. A., & Albert, M. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0194 · Cited by 117 · see citing works
Grove, R. A., Harrington, C. M., Mahler, A., Beresford, I. J. M., Maruff, P. T., Lowy, M. T., Nicholls, A. J., Boardley, R., Berges, A., Nathan, P. J., et al. (2014) · Current Alzheimer Research · doi:10.2174/1567205010666131212110148 · Cited by 109 · see citing works
Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
Panza, F., Logroscino, G., Imbimbo, B. P., & Solfrizzi, V. (2014) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000041 · Cited by 98 · see citing works
Self-citationPanza, F., Solfrizzi, V., Imbimbo, B. P., Tortelli, R., Santamato, A., & Logroscino, G. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.883921 · Cited by 97 · see citing works
Self-citationPhysiological Roles of Amyloid-?? and Implications for its Removal in Alzheimer???s Disease
Bishop, G. M., & Robinson, S. R. (2004) · Drugs & Aging · doi:10.2165/00002512-200421100-00001 · Cited by 94 · see citing works
CAP—advancing the evaluation of preclinical Alzheimer disease treatments
Reiman, E. M., Langbaum, J. B. S., Tariot, P. N., Lopera, F. J., Bateman, R. J., Morris, J. C., Sperling, R. A., Aisen, P. S. S., Roses, A. D., Welsh-Bohmer, K. A., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.177 · Cited by 91 · see citing works
Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease
Imbimbo, B. P., Ottonello, S., Frisardi, V., Solfrizzi, V., Greco, A., Seripa, D., Pilotto, A., & Panza, F. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.11.93 · Cited by 90 · see citing works
Self-citationThe Serotonin-6 Receptor as a Novel Therapeutic Target
Yun, H.-M., & Rhim, H. (2011) · Experimental Neurobiology · doi:10.5607/en.2011.20.4.159 · Cited by 70 · see citing works
Zhu, C. W., Livote, E. E., Scarmeas, N., Albert, M., Brandt, J., Blacker, D., Sano, M. C., & Stern, Y. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.09.015 · Cited by 65 · see citing works
Martiskainen, H., Herukka, S., Stančáková, A., Paananen, J., Soininen, H., Kuusisto, J., Laakso, M., & Hiltunen, M. (2017) · Annals of Neurology · doi:10.1002/ana.24969 · Cited by 64 · see citing works
Mohs, R. C., Shiovitz, T. M., Tariot, P. N., Porsteinsson, A. P., Baker, K. D., & Feldman, P. D. (2009) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181aad585 · Cited by 59 · see citing works
Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients
Panza, F., Seripa, D., Solfrizzi, V., Imbimbo, B. P., Lozupone, M., Leo, A., Sardone, R., Gagliardi, G., Lofano, L., Creanza, B. C., et al. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1241232 · Cited by 59 · see citing works
Self-citationCognitive frailty: a potential target for secondary prevention of dementia
Panza, F., Lozupone, M., Solfrizzi, V., Stallone, R., Bellomo, A., Greco, A., Daniele, A., Seripa, D., & Logroscino, G. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1372424 · Cited by 55 · see citing works
Self-citationAnti-β-Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab
Panza, F., Frisardi, V., Imbimbo, B. P., Seripa, D., Paris, F., Santamato, A., D’Onofrio, G., Logroscino, G., Pilotto, A., & Solfrizzi, V. (2011) · Current Alzheimer Research · doi:10.2174/156720511798192718 · Cited by 53 · see citing works
Self-citationMechanisms of Aβ Plaque Clearance following Passive Aβ Immunization
Morgan, D. (2005) · Neurodegenerative Diseases · doi:10.1159/000090366 · Cited by 52 · see citing works
Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease
Panza, F., Solfrizzi, V., Imbimbo, B. P., Giannini, M., Santamato, A., Seripa, D., & Logroscino, G. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.945522 · Cited by 51 · see citing works
Self-citationAdvances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease
D’Onofrio, G., Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Paroni, G., Cascavilla, L., Seripa, D., & Pilotto, A. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.645534 · Cited by 50 · see citing works
Self-citationTau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium
Seripa, D., Solfrizzi, V., Imbimbo, B. P., Daniele, A., Santamato, A., Lozupone, M., Zuliani, G., Greco, A., Logroscino, G., & Panza, F. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1140039 · Cited by 50 · see citing works
Self-citationEmerging biomarkers and screening for cognitive frailty
Ruan, Q., D’Onofrio, G., Sancarlo, D., Greco, A., Lozupone, M., Seripa, D., Panza, F., & Yu, Z. (2017) · Aging Clinical and Experimental Research · doi:10.1007/s40520-017-0741-8 · Cited by 50 · see citing works
Self-citationWhat lessons can be learned from failed Alzheimer’s disease trials?
Toyn, J. H. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1034690 · Cited by 47 · see citing works
The biochemical aftermath of anti-amyloid immunotherapy
Maarouf, C. L., Daugs, I. D., Kokjohn, T. A., Kalback, W. M., Patton, R., Luehrs, D. C., Masliah, E., Nicoll, J. A. R., Sabbagh, M. N., Beach, T. G., et al. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-39 · Cited by 43 · see citing works
Prevention Trials in Alzheimer’s Disease: Current Status and Future Perspectives
Wang, J., Tan, L., & Yu, J. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150826 · Cited by 23 · see citing works
Hara, H., Ono, F., Nakamura, S., Matsumoto, S., Jin, H., Hattori, N., & Tabira, T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160514 · Cited by 22 · see citing works
ESTABLISHING COMPOSITE COGNITIVE ENDPOINTS FOR USE IN PRECLINICAL ALZHEIMER’S DISEASE TRIALS
Langbaum, J. B. S., Hendrix, S. B., Ayutyanont, N., Bennett, D. A., Shah, R. C., Barnes, L. L., Lopera, F. J., Reiman, E. M., & Tariot, P. N. (2015) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2015.46 · Cited by 21 · see citing works
Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease
Bu, X., Jiao, S., Lian, Y., & Wang, Y. (2015) · Current Alzheimer Research · doi:10.2174/1567205013666151215110114 · Cited by 20 · see citing works
Demattos, R. B., Racke, M. M., Gelfanova, V., Forster, B. M., Knierman, M. D., Bryan, M. T., Hale, J. E., Dean, R. A., Paul, S. M., & Siemers, E. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.05.541 · Cited by 15 · see citing works
Hinerfeld, D. A., Moonis, M., Swearer, J. M., Baker, S. P., Caselli, R. J., Rogaeva, E. A., George‐Hyslop, P. S., & Pollen, D. A. (2007) · Archives of Neurology · doi:10.1001/archneur.64.11.1672 · Cited by 13 · see citing works
Watts, R. J., Chen, M. I.-C., Atwal, J. K., Greve, J. M., Wu, Y., Mortensen, D. L., Varisco, Y., Aldolfsson, O., Pihlgren, M., Pfeifer, A., et al. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.954 · Cited by 8 · see citing works
S1‐02–02: Natural human antibodies targeting amyloid aggregates in intravenous immunoglobulin
Relkin, N. R. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.191 · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966 · see citing works
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306 · see citing works
Srivastava, P., Tripathi, P. N., Sharma, P. A., Nand, S., Singh, S. P., Srivastava, R. K., Shankar, S., & Shrivastava, S. K. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.049 · Cited by 220 · see citing works
Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine
Eid, A., Mhatre, I., & Richardson, J. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.005 · Cited by 164 · see citing works
An update on the novel and approved drugs for Alzheimer disease
Alhazmi, H. A., & Albratty, M. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.10.004 · Cited by 122 · see citing works
“The preliminary results from the BAN2401 studies revealed a treatment-afflicted effect of a reduction in cerebral amyloid load in AD patients, together with a slowing of cognitive deterioration (Panza et al., 2018).”
Fancellu, G., Chand, K., Tomás, D., Orlandini, E., Piemontese, L., Silva, D. F., Cardoso, S. M., Chaves, S., & Santos, M. A. (2019) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2019.1689237 · Cited by 71 · see citing works
Kumar, N. N., Pizzo, M. E., Nehra, G., Wilken-Resman, B., Boroumand, S., & Thorne, R. G. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00548 · Cited by 57 · see citing works
Solfrizzi, V., Agosti, P., Lozupone, M., Custodero, C., Schilardi, A., Valiani, V., Sardone, R., Dibello, V., Lena, L. D., Lamanna, A., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179940 · Cited by 59 · see citing works
Self-citationCeyzériat, K., Zilli, T., Millet, P., Frisoni, G. B., Garibotto, V., & Tournier, B. B. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200304085513 · Cited by 53 · see citing works
Petrushina, I., Hovakimyan, A., Harahap-Carrillo, I. S., Davtyan, H., Antonyan, T., Chailyan, G., Kazarian, K., Antonenko, M., Jullienne, A., Hamer, M. M., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104823 · Cited by 48 · see citing works
Jiang, J., Chang, X., Nie, Y., Shen, Y., Liang, X., Peng, Y., & Chang, M. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00782 · Cited by 42 · see citing works
Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease
Levin, J., Vöglein, J., Quiroz, Y. T., Bateman, R. J., Ghisays, V., Lopera, F., McDade, E., Reiman, E., Tariot, P. N., & Morris, J. C. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12624 · Cited by 40 · see citing works
Bullain, S., & Doody, R. S. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15023 · Cited by 40 · see citing works
Pimenova, A. A., & Goate, A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104785 · Cited by 30 · see citing works
Aggregation Mechanism of Alzheimer’s Amyloid β-Peptide Mediated by α-Strand/α-Sheet Structure
Balupuri, A., Choi, K.-E., & Kang, N. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031094 · Cited by 19 · see citing works
Targets, trials and tribulations in Alzheimer therapeutics
Gharat, R., Dixit, G., Khambete, M., & Prabhu, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176230 · Cited by 18 · see citing works
Jiang, J., Wang, Z., Liang, X., Nie, Y., Chang, X., Xue, H., Li, S., & Chang, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02707 · Cited by 19 · see citing works
Smith, E. N., Lee, J., Prilutsky, D., Zicha, S., Wang, Z., Han, S., & Zach, N. (2023) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2023.2285428 · Cited by 18 · see citing works
2018 Yearbook of Neurorestoratology
Huang, H., Sharma, H. S., Chen, L., Saberi, H., & Mao, G. (2019) · Journal of Neurorestoratology · doi:10.26599/jnr.2019.9040003 · Cited by 18 · see citing works
Transgenerational Interaction of Alzheimer’s Disease with Schizophrenia through Amyloid Evolvability
Takamatsu, Y., Ho, G. J., Waragai, M., Wada, R., Sugama, S., Takenouchi, T., Masliah, E., & Hashimoto, M. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180986 · Cited by 16 · see citing works
Calabria as a Genetic Isolate: A Model for the Study of Neurodegenerative Diseases
Bruno, F., Laganà, V., Lorenzo, R. D., Bruni, A. C., & Maletta, R. (2022) · Biomedicines · doi:10.3390/biomedicines10092288 · Cited by 15 · see citing works
Mitophagy in Alzheimer’s Disease: A Bibliometric Analysis from 2007 to 2022
Wang, H., Yan, X., Zhang, Y., Wang, P., Li, J., & Zhang, X. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230139 · Cited by 9 · see citing works
Xiao, S., Song, L., Li, J., Wang, H., Yu, N., Wang, Z., Zhang, Y., He, J., & Hung, T. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190874 · Cited by 9 · see citing works
Sun, D., Qiao, Y., Jiang, X., Li, P., Kuai, Z., Gong, X., Liu, D., Fu, Q., Sun, L., He, L., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00020 · Cited by 7 · see citing works
PET Imaging of Amyloid and Tau in Alzheimer’s Disease
Okamura, N., & Harada, R. (2022) · Springer eBooks · doi:10.1007/978-981-16-7977-3_19 · Cited by 3 · see citing works
Lian, Q., Sun, Q., Han, X., Ma, H., Guo, J., Wen, B., Wang, P. Y., Li, R., Shan, A., Cui, T., et al. (2026) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2026.2671206 · Cited by 2 · see citing works
Nanomedical drug delivery for neurodegenerative disease
Kaur, N., Kumar, V., Mahender, T., Maji, I., Mahajan, S., Aalhate, M., Singh, P. K., & Sahu, S. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85544-0.00016-2 · Cited by 2 · see citing works
Park, H., Kwon, H. S., Lee, K., Kim, Y. E., Son, J., Choi, N.-Y., Han, M., Park, D. W., Kim, S., & Koh, S. (2024) · Aging · doi:10.18632/aging.205489 · Cited by 2 · see citing works
In search of Alzheimer’s disease treatment methods: trends of clinical trials
Pakulaite-Kazliene, G., Regelskytė, V., Audronytė, E., Kuzmickienė, J., & Kaubrys, G. (2018) · Neurologijos seminarai · doi:10.29014/ns.2018.03 · Cited by 1 · see citing works
Antibodies against Alzheimer's: Pioneering a New Era in Treatment Strategies
Verma, M., Singh, N. K., & Siddique, M. U. M. (2025) · Current Bioactive Compounds · doi:10.2174/0115734072347198241226113039 · Cited by 1 · see citing works
Smith, E. N., Lee, J. H., Prilutsky, D., Zicha, S., Wang, Z., Han, S., & Zach, N. (2023) · medRxiv · doi:10.1101/2023.02.27.23286529 · Cited by 1 · see citing works
Present and Future Therapies for Alzheimer’s Disease
Nagase, H., & Nakayama, K. (2018) · InTech eBooks · doi:10.5772/intechopen.75449
Latest Developments in Preclinical Alzheimer’s Disease
Farlow, M. R. (2019) · touchREVIEWS in Neurology · doi:10.17925/usn.2019.15.1.12
Exploring the Efficacy of Anti-amyloid-β Therapeutics in Treating Alzheimer Disease
Downey, C. (2022) · Youth STEM Matters · doi:10.51892/ysm.1.202201
Jiang, J., Chang, X., Nie, Y., Shen, Y., Liang, X., Xu, K., Peng, Y., & Chang, M. (2019) · doi:10.21203/rs.2.17059/v1
The Amyloid Cascade Hypothesis Has to Deliver, Finally
Behl, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-31570-1_15
Different drugs used as therapeutic targets against AD till date
Nahar, M., Khan, A. G., Rai, R., & Jat, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15540-6.00009-4
Review of drugs effective in Alzheimer's disease
Dawood, S. H., & Zavadsky, S. P. (2024) · Glavvrač (Chief Medical Officer) · doi:10.33920/med-03-2412-13
Trends in Research on Gantenerumab for Alzheimer’s Disease: A Bibliometric and Thematic Analysis
Abdelwahab, S. İ., Taha, M. M. E., Alfaifi, H. A., Alzahrani, A. H., Aljahdali, I. A., Oraibi, O., Ali, S., Oraibi, B., Farasani, A. M., Jerah, A. A., et al. (2025) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273349645250324040257
From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials
Verma, M., & Singh, N. K. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01793-0
Die Amyloid-Kaskaden-Hypothese muss endlich liefern
Behl, C. (2026) · Springer eBooks · doi:10.1007/978-3-662-72210-7_15
- Authors
- Panza, F., Seripa, D., Lozupone, M., Solfrizzi, V., Imbimbo, B. P., Barulli, M. R., Tortelli, R., Capozzo, R., Bisceglia, P., Dimitri, A., Stallone, R., Dibello, V., Quaranta, N., Daniele, A., Bellomo, A., Greco, A., & Logroscino, G.
- Affiliations
- Casa Sollievo della Sofferenza (IT)
- University of Bari Aldo Moro (IT)
- Chiesi (Italy) (IT)
- Università Cattolica del Sacro Cuore (IT)
- Corresponding author
- Panza, Francesco
- ORCID
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-10-16
- Volume
- 18
- Issue
- 1
- Pages
- 25-35
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2766042976
- Cited by
- 41
- References
- 89
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 4 · 2023: 4 · 2022: 6 · 2021: 2 · 2020: 6 · 2019: 9 · 2018: 5
- FWCI
- 0.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Biological Therapy (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale (PRIN) (2009E4RM4Z)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- solanezumab, gantenerumab, Alzheimer's disease, anti-amyloid monoclonal antibodies, autosomal dominant Alzheimer's disease, sporadic Alzheimer's disease, secondary prevention, preclinical Alzheimer's disease, amyloid hypothesis
- MeSH terms
- Alzheimer Disease, Antibodies, Monoclonal, Clinical Trials as Topic, Humans, Mutation, Amyloid beta-Peptides, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
